Cargando…

Traditional Chinese medicine improves myasthenia gravis by regulating the symbiotic homeostasis of the intestinal microbiota and host

Myasthenia gravis (MG) is an autoimmune disease caused by autoantibodies that is dependent on T-cell immunity and complement participation and mainly involves neuromuscular junctions. In this study, 30 patients with myasthenia gravis were selected and divided into pretreatment (Case group) and postt...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Mingli, Liu, Li, Liu, Fanzhao, Liu, Lei, Liu, Zhijuan, Gao, Yanli, Cao, Jianxi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9852828/
https://www.ncbi.nlm.nih.gov/pubmed/36687653
http://dx.doi.org/10.3389/fmicb.2022.1082565
_version_ 1784872744461008896
author Zhao, Mingli
Liu, Li
Liu, Fanzhao
Liu, Lei
Liu, Zhijuan
Gao, Yanli
Cao, Jianxi
author_facet Zhao, Mingli
Liu, Li
Liu, Fanzhao
Liu, Lei
Liu, Zhijuan
Gao, Yanli
Cao, Jianxi
author_sort Zhao, Mingli
collection PubMed
description Myasthenia gravis (MG) is an autoimmune disease caused by autoantibodies that is dependent on T-cell immunity and complement participation and mainly involves neuromuscular junctions. In this study, 30 patients with myasthenia gravis were selected and divided into pretreatment (Case group) and posttreatment (Treatment group) and 30 healthy volunteers (CON group) were included. Among them, the treatment group was treated with Modified Buzhong Yiqi Decoction (MBZYQD), and the levels of antibodies such as AChR, Musk and Titin in blood and intestinal microbiota were compared before treatment (Case group), after treatment (Treatment group) and in healthy volunteers (CON group). The results showed that after treatment with MBZYQD, the antibody levels of AChR, MuSK, and Titin and the inflammatory factor level of IL-6, IL-1β, and IL-22 in MG patients decreased significantly and nearly returned to a healthy level. In addition, after treatment with MBZYQD, the diversity, structure and function of intestinal microorganisms in MG patients also recovered to a healthy level. At the phylum level, the relative abundance of Proteobacteria in the Case group increased significantly, accompanied by a significant decrease in the relative abundance of Bacteroides compared with that in the CON group, the relative abundance of Proteobacteria and Bacteroides in the Treatment group was similar to that in the CON group. At the genus level, the relative abundance of Shigella in the Case group was significantly increased, accompanied by a significant decrease in the relative abundance of Prevotella, and the relative abundance of Shigella and Prevotella in Treatment group was similar to that in the CON group. Moreover, the fluorobenzoate degradation pathway (KO00364) was significantly increased in the Case group, while this pathway was significantly decreased in the Treatment group. In conclusion, MBZYQD can improve the immune function of the host by regulating the diversity, structure and function of the intestinal microbiota to treat myasthenia gravis.
format Online
Article
Text
id pubmed-9852828
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98528282023-01-21 Traditional Chinese medicine improves myasthenia gravis by regulating the symbiotic homeostasis of the intestinal microbiota and host Zhao, Mingli Liu, Li Liu, Fanzhao Liu, Lei Liu, Zhijuan Gao, Yanli Cao, Jianxi Front Microbiol Microbiology Myasthenia gravis (MG) is an autoimmune disease caused by autoantibodies that is dependent on T-cell immunity and complement participation and mainly involves neuromuscular junctions. In this study, 30 patients with myasthenia gravis were selected and divided into pretreatment (Case group) and posttreatment (Treatment group) and 30 healthy volunteers (CON group) were included. Among them, the treatment group was treated with Modified Buzhong Yiqi Decoction (MBZYQD), and the levels of antibodies such as AChR, Musk and Titin in blood and intestinal microbiota were compared before treatment (Case group), after treatment (Treatment group) and in healthy volunteers (CON group). The results showed that after treatment with MBZYQD, the antibody levels of AChR, MuSK, and Titin and the inflammatory factor level of IL-6, IL-1β, and IL-22 in MG patients decreased significantly and nearly returned to a healthy level. In addition, after treatment with MBZYQD, the diversity, structure and function of intestinal microorganisms in MG patients also recovered to a healthy level. At the phylum level, the relative abundance of Proteobacteria in the Case group increased significantly, accompanied by a significant decrease in the relative abundance of Bacteroides compared with that in the CON group, the relative abundance of Proteobacteria and Bacteroides in the Treatment group was similar to that in the CON group. At the genus level, the relative abundance of Shigella in the Case group was significantly increased, accompanied by a significant decrease in the relative abundance of Prevotella, and the relative abundance of Shigella and Prevotella in Treatment group was similar to that in the CON group. Moreover, the fluorobenzoate degradation pathway (KO00364) was significantly increased in the Case group, while this pathway was significantly decreased in the Treatment group. In conclusion, MBZYQD can improve the immune function of the host by regulating the diversity, structure and function of the intestinal microbiota to treat myasthenia gravis. Frontiers Media S.A. 2023-01-06 /pmc/articles/PMC9852828/ /pubmed/36687653 http://dx.doi.org/10.3389/fmicb.2022.1082565 Text en Copyright © 2023 Zhao, Liu, Liu, Liu, Liu, Gao and Cao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Zhao, Mingli
Liu, Li
Liu, Fanzhao
Liu, Lei
Liu, Zhijuan
Gao, Yanli
Cao, Jianxi
Traditional Chinese medicine improves myasthenia gravis by regulating the symbiotic homeostasis of the intestinal microbiota and host
title Traditional Chinese medicine improves myasthenia gravis by regulating the symbiotic homeostasis of the intestinal microbiota and host
title_full Traditional Chinese medicine improves myasthenia gravis by regulating the symbiotic homeostasis of the intestinal microbiota and host
title_fullStr Traditional Chinese medicine improves myasthenia gravis by regulating the symbiotic homeostasis of the intestinal microbiota and host
title_full_unstemmed Traditional Chinese medicine improves myasthenia gravis by regulating the symbiotic homeostasis of the intestinal microbiota and host
title_short Traditional Chinese medicine improves myasthenia gravis by regulating the symbiotic homeostasis of the intestinal microbiota and host
title_sort traditional chinese medicine improves myasthenia gravis by regulating the symbiotic homeostasis of the intestinal microbiota and host
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9852828/
https://www.ncbi.nlm.nih.gov/pubmed/36687653
http://dx.doi.org/10.3389/fmicb.2022.1082565
work_keys_str_mv AT zhaomingli traditionalchinesemedicineimprovesmyastheniagravisbyregulatingthesymbiotichomeostasisoftheintestinalmicrobiotaandhost
AT liuli traditionalchinesemedicineimprovesmyastheniagravisbyregulatingthesymbiotichomeostasisoftheintestinalmicrobiotaandhost
AT liufanzhao traditionalchinesemedicineimprovesmyastheniagravisbyregulatingthesymbiotichomeostasisoftheintestinalmicrobiotaandhost
AT liulei traditionalchinesemedicineimprovesmyastheniagravisbyregulatingthesymbiotichomeostasisoftheintestinalmicrobiotaandhost
AT liuzhijuan traditionalchinesemedicineimprovesmyastheniagravisbyregulatingthesymbiotichomeostasisoftheintestinalmicrobiotaandhost
AT gaoyanli traditionalchinesemedicineimprovesmyastheniagravisbyregulatingthesymbiotichomeostasisoftheintestinalmicrobiotaandhost
AT caojianxi traditionalchinesemedicineimprovesmyastheniagravisbyregulatingthesymbiotichomeostasisoftheintestinalmicrobiotaandhost